Literature DB >> 14569097

Molecular analysis of the SGLT2 gene in patients with renal glucosuria.

René Santer1, Martina Kinner, Christoph L Lassen, Reinhard Schneppenheim, Paul Eggert, Martin Bald, Johannes Brodehl, Markus Daschner, Jochen H H Ehrich, Markus Kemper, Salvatore Li Volti, Thomas Neuhaus, Flemming Skovby, Peter G F Swift, Jürgen Schaub, Dan Klaerke.   

Abstract

The role of SGLT2 (the gene for a renal sodium-dependent glucose transporter) in renal glucosuria was evaluated. Therefore, its genomic sequence and its intron-exon organization were determined, and 23 families with index cases were analyzed for mutations. In 21 families, 21 different SGLT2 mutations were detected. Most of them were private; only a splice mutation was found in 5 families of different ethnic backgrounds, and a 12-bp deletion was found in two German families. Fourteen individuals (including the original patient with 'renal glucosuria type 0') were homozygous or compound heterozygous for an SGLT2 mutation resulting in glucosuria in the range of 14.6 to 202 g/1.73 m(2)/d (81 - 1120 mmol/1.73 m(2)/d). Some, but not all, of their heterozygous family members had an increased glucose excretion of up to 4.4 g/1.73 m(2)/d (24 mmol/1.73 m(2)/d). Likewise, in index cases with glucosuria below 10 g/1.73 m(2)/d (55 mmol/1.73 m(2)/d) an SGLT2 mutation, if present, was always detected in the heterozygous state. We conclude that SGLT2 plays an important role in renal tubular glucose reabsorption. Inheritance of renal glucosuria shows characteristics of a codominant trait with variable penetrance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569097     DOI: 10.1097/01.asn.0000092790.89332.d2

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  87 in total

Review 1.  Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A DeFronzo
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

Review 2.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

3.  Familial renal glucosuria: a clinicogenetic study of 23 additional cases.

Authors:  HyunKyung Lee; Kyoung Hee Han; Hye Won Park; Jae Il Shin; Chan Jong Kim; Mee Kyung Namgung; Kee Hyuck Kim; Ja Wook Koo; Woo Young Chung; Dae-Yeol Lee; Su-Yung Kim; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2012-07       Impact factor: 3.714

Review 4.  Renal glucose transporters: novel targets for hyperglycemia management.

Authors:  Amanda Mather; Carol Pollock
Journal:  Nat Rev Nephrol       Date:  2010-03-30       Impact factor: 28.314

Review 5.  Inherited epithelial transporter disorders--an overview.

Authors:  M J Bergeron; A Simonin; M Bürzle; M A Hediger
Journal:  J Inherit Metab Dis       Date:  2008-04-14       Impact factor: 4.982

Review 6.  SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys.

Authors:  Frederik H Verbrugge; Pieter Martens; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2017-08

7.  Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.

Authors:  Ivan Sabolic; Ivana Vrhovac; Daniela Balen Eror; Maria Gerasimova; Michael Rose; Davorka Breljak; Marija Ljubojevic; Hrvoje Brzica; Anne Sebastiani; Serge C Thal; Christoph Sauvant; Helmut Kipp; Volker Vallon; Hermann Koepsell
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-18       Impact factor: 4.249

Review 8.  Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.

Authors:  Jagriti Bhatia; Nanda Gamad; Saurabh Bharti; Dharamvir Singh Arya
Journal:  World J Diabetes       Date:  2014-06-15

Review 9.  GLUT, SGLT, and SWEET: Structural and mechanistic investigations of the glucose transporters.

Authors:  Dong Deng; Nieng Yan
Journal:  Protein Sci       Date:  2016-01-04       Impact factor: 6.725

10.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.